Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria in the upper respiratory tract refers to several bacterial species capable of causing acute illnesses, including pharyngitis, sinusitis, otitis media, epiglottitis, and laryngotracheitis. Common pathogenic bacteria include Streptococcus pyogenes (primary cause of strep throat), Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Mycoplasma pneumoniae[1][2][3][4][6]. These organisms enter and colonize the mucosal surface of the respiratory tract, leading to a variety of symptoms due to inflammation, toxin production, and immune evasion. Diagnosis is typically confirmed by microbiological culture or rapid antigen testing. Treatment relies on antibiotics targeting bacterial cell wall or protein synthesis. Inappropriate antibiotic usage can encourage resistance and cause therapeutic complications, emphasizing the need for careful diagnosis and targeted intervention. This entry is not a valid single molecular target for drug development or biomarker usage.
Inhibition of bacterial cell wall synthesis (by β-lactams); Inhibition of protein synthesis (by macrolides)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria in upper respiratory tract.